Ostizeel™ is a clinically formulated joint health supplement designed to reduce pain, control inflammation, and support cartilage protection through a science-backed, multi-pathway mechanism.

A clinically formulated solution for comprehensive osteoarthritis care, combining pain relief, inflammation control, and cartilage protection backed by biomedical research.
Ostizeel™ is a scientifically developed joint health formulation created to address the complex and multifactorial nature of osteoarthritis. We are a research-driven brand committed to offering a clinically proven, safe, and comprehensive solution for joint care. Our mission is to improve the quality of life for individuals affected by osteoarthritis through targeted, multi-pathway support.
Developed from pain science and joint biology to precisely target nociceptive and neuropathic pain pathways in osteoarthritis.
Combines molecular modulation, muscle support, and cartilage protection into a unified clinical strategy for total joint health.
Developed through targeted biomedical research addressing both nociceptive and neuropathic pain with proven clinical outcomes.
Osteoarthritis is a degenerative joint condition that affects millions worldwide, leading to joint pain, inflammation, and reduced mobility. It commonly impacts the knees, hips, spine, hands, and feet, and is characterized by the breakdown of cartilage, inflammation of the synovial membrane, and weakening of ligaments and muscles. Ostizeel™ has been developed as an innovative response to these challenges.
Ostizeel™ is a synergistic formulation of Palmitoylethanolamide (PEA) and Cucumis sativus extract, designed to act on both nociceptive and neuropathic pain pathways. These two mechanisms are central to the development and persistence of osteoarthritis pain. Nociceptive pain arises from joint tissue damage and inflammation, while neuropathic pain results from nerve sensitization and neuroinflammation. By addressing both, Ostizeel™ delivers targeted and lasting relief.

Ostizeel™ has been scientifically formulated to modulate critical molecular mechanisms that contribute to osteoarthritis progression. It targets mast cells, TRPV1 receptors, PPAR-α, and microglial cells all of which play key roles in pain transmission and inflammation. The result is a dual-action response that reduces both inflammatory and neuropathic pain.
In addition to its analgesic action, Ostizeel™ offers chondroprotective benefits by inhibiting matrix metalloproteinases (MMPs) enzymes responsible for cartilage breakdown. The formulation also downregulates major inflammatory biomarkers such as TNF-α, IL-6, IL-1β, and NF-κB, helping reduce joint inflammation and slow disease progression.